Priors rates this Established — 91 out of 100, updated weekly. Yes — this looks well established. On the claim that basal insulin analogues (insulin glargine and detemir) provide equivalent glycaemic control with significantly less nocturnal hypoglycaemia compared with NPH insulin in people with type 2 diabetes, its four-agent AI review panel weighs 17 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Type 2 Diabetes Management review.